After serving less than two years in the post, Scott Gottlieb officially exited his post as the Food and Drug Administration’s commissioner Tuesday, April 2, handing over the reins to interim chief Ned Sharpless.
Gottlieb during his final days as commissioner, according to a PMLiVE report, touched on several key issues, including rising insulin costs, artificial intelligence in medical devices, cannabis-based medicines and illegal sales of opioids online.
“A drug that’s nearly a century old should not have a list price that increases between 15-17% annually,” Gottlieb said in a statement. “American patients who rely on insulin to live deserve to have high-quality, affordable options.”
To read the full report on PMLiVE, click here.